title: Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction.
abstract: We investigated the prognostic importance of plasma myeloperoxidase levels in patients with ST-elevation myocardial infarction (STEMI) at long-term follow-up, and we analyzed the correlations between plasma myeloperoxidase levels and other biochemical values. We evaluated 73 consecutive patients (56 men; mean age, 56 ± 11 yr) diagnosed with acute STEMI and 46 age- and sex-matched healthy control participants. Patients were divided into 2 groups according to the median myeloperoxidase level (Group 1: plasma myeloperoxidase ≤ 68 ng/mL; and Group 2: plasma myeloperoxidase > 68 ng/mL). Patients were monitored for the occurrence of major adverse cardiovascular events (MACE), which were defined as cardiac death; reinfarction; new hospital admission for angina; heart failure; and revascularization procedures. The mean follow-up period was 25 ± 16 months. Plasma myeloperoxidase levels were higher in STEMI patients than in control participants (82 ± 34 vs 20 ± 12 ng/mL; P = 0.001). Composite MACE occurred in 12 patients with high myeloperoxidase levels (33%) and in 4 patients with low myeloperoxidase levels (11%) (P = 0.02). The incidences of nonfatal recurrent myocardial infarction and verified cardiac death were higher in the high-myeloperoxidase group. In multivariate analysis, high plasma myeloperoxidase levels were independent predictors of MACE (odds ratio = 3.843; <95% confidence interval, 1.625-6.563; P = 0.003). High plasma myeloperoxidase levels identify patients with a worse prognosis after acute STEMI at 2-year follow-up. Evaluation of plasma myeloperoxidase levels might be useful in determining patients at high risk of death and MACE who can benefit from further aggressive treatment and closer follow-up.
authors.affiliation: Department of Cardiology, Erciyes University School of Medicine, 38039 Kayseri, Turkey. drmgkaya@yahoo.com
authors.forename: Mehmet Gungor
authors.initials: MG
authors.lastname: Kaya
authors.forename: Ridvan
authors.initials: R
authors.lastname: Yalcin
authors.forename: Kaan
authors.initials: K
authors.lastname: Okyay
authors.forename: Fatih
authors.initials: F
authors.lastname: Poyraz
authors.forename: Nilufer
authors.initials: N
authors.lastname: Bayraktar
authors.forename: Hatice
authors.initials: H
authors.lastname: Pasaoglu
authors.forename: Bulent
authors.initials: B
authors.lastname: Boyaci
authors.forename: Atiye
authors.initials: A
authors.lastname: Cengel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000097:blood / Q000201:enzymology / Q000453:epidemiology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000201:enzymology / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood / Q000201:enzymology* / Q000401:mortality / Q000628:therapy; D009204:Myocardial Revascularization; D016017:Odds Ratio; D010359:Patient Readmission; D009195:Peroxidase / Q000097:blood*; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014421:Turkey / Q000453:epidemiology; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D015415:Biomarkers; D009195:Peroxidase